NASDAQ: NBTXNanobiotix Sa Stock
$5.10+0.16 (+3.24%)
Updated Jun 8, 2023
NBTX Price
$5.10
Fair Value Price
$7.35
Market Cap
$177.87M
52 Week Low
$1.75
52 Week High
$7.76
P/E
-2.83x
P/B
-5.98x
P/S
25.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.25M
Earnings
-$60.68M
Gross Margin
100%
Operating Margin
-903.85%
Profit Margin
-1,194.3%
Debt to Equity
-3.21
Operating Cash Flow
-$39M
Beta
1.11
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NBTX Overview
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NBTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NBTX ($5.10) is undervalued by 30.62% relative to our estimate of its Fair Value price of $7.35 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NBTX ($5.10) is significantly undervalued by 30.62% relative to our estimate of its Fair Value price of $7.35 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NBTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NBTX due diligence checks available for Premium users.
Be the first to know about important NBTX news, forecast changes, insider trades & much more!
NBTX News
Valuation
NBTX fair value
Fair Value of NBTX stock based on Discounted Cash Flow (DCF)
Price
$5.10
Fair Value
$7.35
Undervalued by
30.62%
NBTX ($5.10) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NBTX ($5.10) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NBTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NBTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.83x
Industry
11.75x
Market
52.58x
NBTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5.98x
Industry
5.24x
NBTX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
NBTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NBTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$63.6M
Liabilities
$92.4M
Debt to equity
-3.21
NBTX's short-term assets ($57.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NBTX's short-term assets ($57.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NBTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NBTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NBTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NBTX vs Biotech Stocks
Nanobiotix Sa Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.